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Diagnostic accuracy of axillary nodal ultrasound after neoadjuvant
chemotherapy in node-positive breast cancer patients: A validation study
Syeda Sakina Abidi,1 Lubna Mushtaque Vohra,2 Asad Ali Kerawala,3 Imrana Masroor,4 Muhammad Umair Tahseen5

Abstract
Objective: To determine the accuracy and false negative rate of axillary ultrasound compared to sentinel node
biopsy.
Method: The retrospective study was conducted at the Aga Khan University Hospital, Karachi, from February 1 to
March 31, 2021, and comprised data of breast cancer patients who had undergone neo-adjuvant chemotherapy
followed by axillary lymph node dissection or axillary disease diagnosed using lymph node biopsy or sentinel lymph
node biopsy between January 1, 2016, and December 30, 2020. After receiving neoadjuvant chemotherapy, axillary
ultrasound findings were compared with histopathology of lymph nodes. Data was analysed using SPSS 22.
Results: Of the 155 patients evaluated, 104(67.1%) were diagnosed with negative axillary lymph nodes and
51(32.9%) were diagnosed with positive axillary lymph nodes post-chemotherapy. The overall mean age was
51.13±1.3 years. When histopathology results were compared with those of axillary ultrasound, 36(23.2%) cases
turned out to be true positive, while 23(14,8%) were false negative, yielding a positive predictive value of 75% and
negative predictive value of 65%. Axillary ultrasound had 75% accuracy, false negative rate 30%, sensitivity 61% and
specificity 84.4%.
Conclusion: Axillary ultrasound was found to be fairly useful, but not completely reliable, in identifying positive
lymph nodes, .
Keywords: Neoadjuvant chemotherapy, Ultrasound axilla, Sensitivity, False negative rate.
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Introduction
For the past few decades, axillary nodal status has been
the cornerstone in breast cancer staging, making axillary
surgery part and parcel of breast cancer surgery.1 Axillary
lymph node dissection (ALND), however, comes with
significant morbidity of swelling in the arms, numbness
and restricted arm movements in up to 40% patients.2
With increasing knowledge of tumour biology as a more
important diagnostic factor and milestones achieved in
the de-escalation of breast surgery to reduce morbidity,
the need for ALND was questioned. This led to the
concept of sentinel lymph node biopsy (SLNB) which now
represents routine care in node-negative, early breast
cancer patients.3 Although neo-adjuvant chemotherapy
(NACT) allowed breast conservation surgeries to be
offered to patients who presented with advance disease,
standard ALND remained in practice in post-neo-adjuvant
settings. This was mostly because of concern that altered
lymphatic drainage pertaining to post-systemic
treatment fibrosis may lead to inaccurate SLNB results.4
Nevertheless, enthusiasm to tailor breast and axillary
surgery grew with the knowledge that a number of
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individuals who receive NACT achieve a pathologically
complete response (pCR), defined as no residual
infiltrating disease in the breast and the axillary lymph
nodes. The rate of achieving pCR strongly correlated with
subtypes of breast cancer.5
Two large multi-centre prospective clinical trials
subsequently validated the feasibility of SLNB in
individuals who had positive axillary nodal disease at
presentation and achieved a clinically node-negative
status after receiving NACT. Both the studies reported a
false negative rate (FNR) of 12.6% to 14.2% for SLNB which
was above the accepted threshold of 10%.6-8 The FNR was
optimised to <10% using dual tracer, removing three
sentinel nodes and clipping biopsied nodes.9
Currently available imaging modalities for pre-operative
evaluation of axilla in breast cancer patients include
mammogram (MMG), axillary ultrasound (aUS), computed
tomography (CT) and magnetic resonance imaging (MRI).
MMG has diagnostic accuracy of 79.5%, but is unreliable
as part of axilla may not be visualised on routine MMG. CT
scan and MRI are not usually used for general evaluation
of axilla as they are expensive, but are helpful when the
extent of disease needs to be evaluated.10 Thus, aUS is the
imaging of choice for initial axillary assessment of
patients, but there is significant difference of reported
sensitivity (27-94%) and specificity (53-100%).11 Despite
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being operator-dependent, it has outperformed other
imaging techniques with the advantage of being less
expensive and non-invasive, thereby becoming routine
practice.12 In an attempt to decrease FNR, studies have
explored the use of US to identify nodes for SLNB and
reported an FNR decrease to 9.8% when used with dual
tracer techniques.13 Sensitivity 71% and specificity 88%
was reported using aUS with 83% negative predictive
value (NPV) and 29% FNR.14
Formal re-staging of axilla post-NACT was adopted at the
study site in 2015. The current study was planned to
determine the accuracy and FNR of aUS compared to
SLNB since the change.

Materials and Methods
The retrospective study was conducted at the Aga Khan
University Hospital (AKUH), Karachi, from February 1 to
March 31, 2021, and comprised data of breast cancer
patients who had undergone NACT followed by ALND or
SLNB between January 1, 2016, and December 30, 2020.
After exemption from the institutional ethics review
committee, hospital database was used to identify
patients and data was collected on a self-designed
questionnaire. Ultrasound axilla reports of patients who
received primary NACT were matched with
histopathology reports of axillary nodes after definitive
surgery which is the gold standard, categorised as
positive for lymph nodes with residual tumour, and
negative on the absence of such findings. Data was also
obtained on age, grade and biology of tumour, stage of
breast cancer, and the chemotherapy regimen used. The
sensitivity and specificity of aUS was identified through
receiver operating characteristic (ROC) curve. Data was
analysed using SPSS 22. Descriptive data was reported for
quantitative and qualitative variables as mean and
standard deviation, median and interquartile range (IQR),
and frequencies and percentages, as appropriate. Chisquare test was used to test positive predictive value
(PPV) and negative predictive value (NPV) of aUS in
relation to post-ALND and immunohistochemistry. ROC
curve was used to test the specificity and sensitivity of
aUS. P<0.05 was considered statistically significant.

Results
Of the 155 patients evaluated, 104(67.1%) were
diagnosed with negative axillary lymph nodes and
51(32.9%) were diagnosed with positive axillary lymph
nodes post-chemotherapy. The overall mean age was
51.13±1.3 years. The median time for follow-up from the
start of NACT to surgery was 6 months (IQR: 3-9 months).
Demographic and baseline clinical data was noted
(Table-1).
J Pak Med Assoc (Suppl. 1)

Table-1: Baseline characteristics of tumour and patient demographics.
Characterstics

No. (%)

Age (mean), years
51.13±1.13
Menopausal status
Premenopausal
63 (40.6%)
Perimenopausal
71 (45.8%)
Postmenopausal
21 (13.5%)
Receptor Status
ER-/PR-/Her264 (41.5%)
ER/PR+/HEr2+
30 (19.5%)
ER/PR+/Her245 (29.2%)
ER/PR-/HER2+
15 (9.7%)
Size of Invasive focus
Complete Response
43 (27.7%)
<1 cm
41 (26.4%)
1-2 cm
35 (22.6%)
>2 cm
36 (23.2%)
Grade of cancer
Grade I
1 (0.6%)
Grade II
90 (58%)
Grade III
64 (41.2%)
Clinical Stage
T1N0
7 (4.5%)
T1N1
14 ( 9%)
T2N0
21 (13.5%)
T2N1
83 (53.5%)
T3N0
4 (2.5%)
T3N1
18 (11.6%)
T4N0
2 (1.3%)
T4N1
6 (3.8%)
Histopathology Findings
IDC
5 (3.2%)
Others
150 (96.8%)
Lymph nodes status post NACT
Negative axillary lymph nodes post NACT
101 (67.1%)
Positive axillary lymph nodes post NACT
54 (32.9%)
Total No Of Sentinel Nodes Retrieved
No Sentinel lymph node retrieved
33 (42.2%)
1
5 (0.1%)
2
16 (0.6%)
3
33 (25.5%)
>3
22 (24.4%)
Axillary lymph nodes positive on histopathology after SLN Biopsy
None
44 (75.9%)
1
11 (19%)
2
2 (3.4%)
3 or >3
1 (1.7%)
Axillary lymph node dissection given
112 (72.2%)
Nodes recovered in ALND
None
3 (2.2%)
<3
1 (0.7%)
<10
7 (5.1%)
<20
63 (45.7%)
<30
34 (24.6%)
<40
5 (3.6%)
No. of positive lymph nodes after ALND
None
55 (48.2%)
<3
30 (26.3%)
<5
8 (7.1%)
<10
15 (13.1%)
<20
6 (5.3%)
SD: Standard deviation, ER: Oestrogen receptor, PR: Progesterone receptor, HER2: Human
epidermal growth factor receptor 2, SLN: Sentinel lymph node, IDC: Invasive ductal carcinoma,
NACT: Neo-adjuvant chemotherapy, ALND: Axillary lymph node dissection.
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Table-2: Diagnostic characteristics of ultrasound (US) modality.

Residual Disease on Histopathology
No Residual Disease on Histopathology
Accuracy= 75%

Axillary US post NACT
Residual Disease

Axillary US post NACT
No Residual Disease

True Positive n=31
False Positive n=20
Positive Predictive Value = 75%

False Negative n=36
True Negative n=68
Negative Predictive Value = 65%

Sensitivity=61%
Specificity=84.4%
False Negative Rate =30%

NACT: Neo-adjuvant chemotherapy.

Table-3: Diagnostic PPV and NPV according to tumour phenotype.
Tumour histopathological
subtype
ER+ HER2ER+ HER2+
ER- HER2+
ER- HER2-

Positive Predictive
Value (PPV)

Negative Predictive
Value (NPV)

100%
64%
82%
60%

50%
57%
71%
75%

ER: Oestrogen receptor, HER2: Human epidermal growth factor receptor 2.

aUS: Axillary ultrasound, SLNB: Sentinel lymph node biopsy,
ALND: Axillary lymph node dissection.
SLNB is showing false negative rate (FNR) of 12.5% while aUS is showing FNR of 30%.

Figure-2: Boughey's algorithm.

(Standard error=0.04; p=0.001).
Diagnostic PPV and NPV according to tumour phenotype
were noted separately (Table-3). SLNB had a FNR 12.5%
compared to aUS FNR 30% (Figure-2).

Discussion

Figure-1: ROC: Receiver operating characteristic (ROC) curve illustrating the sensitivity
and specificity of axillary ultrasound (aUS). Area under curve (AUC) = 0.73.

When histopathology results were compared with those
of aUS, 36 cases turned out to be true positive (TP), while
23(%) were false negative (FN), yielding a PPV of 75% and
NPV of 65%. The aUS had 75% accuracy, FNR 30%,
sensitivity 61% and specificity 84.4% (Table-2).
ROC curve showed 61% aUS sensitivity and 84% aUS
specificity (Figure-1). The area under curve (AUC) was 0.73

The aUS is a vital adjunct to breast imaging in the staging
of breast cancers. The lymph nodal status not only guides
the treatment, but also provides valuable prognostic
information. The major lymphatic drainage from the
breast is to the ipsilateral axillary nodes which are best
assessed by US. They may be categorised as suspicious
(thickened cortex, loss of fatty hilum) or normal (having
an intact hilum, cortex <3mm). Concordance in US
findings and histopathology may help avoid axillary
surgery and its associated morbidity in certain patients.
In the current study, aUS FNR in post-NACT patients was
30%. FNR as low as 2% with targeted axillary dissection
has been reported in studies.15 Targeted axillary
dissection, however, involves additional cost and
procedures, like clip placement at the time of biopsy.
Historically, FNR <10% has been considered significant to
use the proposed method of nodal identification. FNR
9.8% can be achieved with a combination of aUS and
Vol. 72, No. 1 (Suppl. 1), January 2022
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SLNB post-chemotherapy.12

Source of Funding: None.

The current study showed 61% sensitivity of aUS in
diagnosing axillary metastasis post-NACT. Other studies
have shown sensitivities ranging from 50% to 66% in
different settings.13,16,17 The specificity in the current
study was 84%, which was comparable with other studies
ranging from 37% to 92%.18

References

Studies20,21 suggested that different subtypes of breast
cancer affect the diagnostic aUS accuracy, and this should
be kept in mind before making decisions. The studies
reported an overall sensitivity of 60%,19,20 which is in
concordance with the current study. The specificity was
65%, which is lower than the current finding. The overall
PPV and NPV were 82% and 38.5% compared to 75% and
65% in the current study. Higher PPV means that if there
are suspicious US findings, there is high probability of the
node being involved with cancer and the patient can
proceed with an axillary dissection and prevent an
unnecessary SLNB.
The studies19,20 pointed towards non-luminal subtypes
having a higher sensitivity compared to luminal
subtypes, while the specificity was the same for both.
The sensitivity was highest in triple-negative cancers.
Similarly, the PPV was highest for luminal A subtype and
the NPV was the highest for triple-negative cancer.19,20
The current subset analysis of tumour phenotype
showed similar results (Table-3). A study also presented
the same results with almost 100% PPV for luminal A
subtype.21
A newer approach to avoid unnecessary axillary
dissection is called the Systemic Sonographic Axillary
Staging. Any suspicious nodes after completion of NACT
undergoes repeat needle biopsy, and axillary surgery is
planned according to the status of biopsy results.22
The current study has limitations of having single-centre,
retrospective data. Besides, the role of repeat biopsy of
suspicious axillary nodes and effects of tumour
phenotype on re-staging of axillary disease need further
exploration.

1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

Conclusion
The aUS was found to be a fairly useful, but not
completely reliable, tool for identifying positive lymph
nodes. Further intervention is necessary for diagnosis.
Thus, histopathology remains the gold standard to
identify axillary metastasis.
Disclaimer: None.
Conflict of Interest: None.
J Pak Med Assoc (Suppl. 1)

12.

13.

Fisher CS, Margenthaler JA, Hunt KK, Schwartz T. The Landmark
Series: Axillary Management in Breast Cancer. Ann Surg Oncol
2020;27:724-9. doi: 10.1245/s10434-019-08154-5.
Dang S, Saini SK, Pattanayak M. Surgical management of axilla:
controversy and care. Int Surg J 2019;6:718-23. DOI:
10.18203/2349-2902.isj20190514
Yuan Q, Hou J, He Y, Liao Y, Zheng L, Wu G. Minimize the extent
and morbidity of axillary dissection for node-positive breast
cancer patients: implementation of axillary lymph node dissection
based on breast lymphatics level. BMC Cancer 2021;21:293. doi:
10.1186/s12885-021-08024-y.
Wong SM, Weiss A, Mittendorf EA, King TA, Golshan M. Surgical
Management of the Axilla in Clinically Node-Positive Patients
Receiving Neoadjuvant Chemotherapy: A National Cancer
Database Analysis. Ann Surg Oncol 2019;26:3517-25. doi:
10.1245/s10434-019-07583-6.
Díaz-Casas SE, Castilla-Tarra JA, Pena-Torres E, Orozco-Ospino M,
Mendoza-Diaz S, Nuñez-Lemus M, et al. Pathological Response to
Neoadjuvant Chemotherapy and the Molecular Classification of
Locally Advanced Breast Cancer in a Latin American Cohort.
Oncologist 2019;24:e1360-70. doi: 10.1634/theoncologist.20190300.
Srour MK, Tseng J, Luu M, Alban RF, Giuliano AE, Chung A.
Patterns in the Use of Axillary Operations for Patients with NodePositive Breast Cancer After Neoadjuvant Chemotherapy: A
National Cancer Database (NCDB) Analysis. Ann Surg Oncol
2019;26:3305-11. doi: 10.1245/s10434-019-07540-3.
Laws A, Dillon K, Kelly BN, Kantor O, Hughes KS, Gadd MA, et al.
Node-Positive Patients Treated with Neoadjuvant Chemotherapy
Can Be Spared Axillary Lymph Node Dissection with Wireless NonRadioactive Localizers. Ann Surg Oncol 2020;27:4819-27. doi:
10.1245/s10434-020-08902-y.
Tinterri C, Canavese G, Bruzzi P, Dozin B. NEONOD 2: Rationale and
design of a multicenter non-inferiority trial to assess the effect of
axillary surgery omission on the outcome of breast cancer
patients presenting only micrometastasis in the sentinel lymph
node after neoadjuvant chemotherapy. Contemp Clin Trials
Commun 2019;17:e100496. doi: 10.1016/j.conctc.2019.100496.
Damin AP, Zancan M, Melo MP, Biazus JV. Sentinel lymph node
biopsy after neoadjuvant chemotherapy in patients with nodepositive breast cancer: guiding a more selective axillary approach.
Breast Cancer Res Treat 2021;186:527-34. doi: 10.1007/s10549020-06011-8.
Choi HY, Park M, Seo M, Song E, Shin SY, Sohn YM. Preoperative
Axillary Lymph Node Evaluation in Breast Cancer: Current Issues
and Literature Review. Ultrasound Q 2017;33:6-14. doi:
10.1097/RUQ.0000000000000277.
Lowes S, Leaver A, Cox K, Satchithananda K, Cosgrove D, Lim A.
Evolving imaging techniques for staging axillary lymph nodes in
breast
cancer.
Clin
Radiol
2018;73:396-409.
doi:
10.1016/j.crad.2018.01.003.
You S, Kang DK, Jung YS, An YS, Jeon GS, Kim TH. Evaluation of
lymph node status after neoadjuvant chemotherapy in breast
cancer patients: comparison of diagnostic performance of
ultrasound, MRI and ¹?F-FDG PET/CT. Br J Radiol
2015;88:20150143. doi: 10.1259/bjr.20150143.
Boughey JC, Ballman KV, Hunt KK, McCall LM, Mittendorf EA,
Ahrendt GM, et al. Axillary Ultrasound After Neoadjuvant
Chemotherapy and Its Impact on Sentinel Lymph Node Surgery:
Results From the American College of Surgeons Oncology Group
Z1071 Trial (Alliance). J Clin Oncol 2015;33:3386-93. doi:
10.1200/JCO.2014.57.8401.

S-29
14.

15.

16.

17.

18.

Peppe A, Wilson R, Pope R, Downey K, Rusby J. The use of
ultrasound in the clinical re-staging of the axilla after neoadjuvant
chemotherapy (NACT). Breast 2017; 35:104-8. doi:
10.1016/j.breast.2017.05.015.
Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM,
Gilcrease MZ, et al. Improved Axillary Evaluation Following
Neoadjuvant Therapy for Patients With Node-Positive Breast
Cancer Using Selective Evaluation of Clipped Nodes:
Implementation of Targeted Axillary Dissection. J Clin Oncol
2016;34:1072-8. doi: 10.1200/JCO.2015.64.0094.
Ha SM, Cha JH, Kim HH, Shin HJ, Chae EY, Choi WJ. Diagnostic
performance of breast ultrasonography and MRI in the
prediction of lymph node status after neoadjuvant
chemotherapy for breast cancer. Acta Radiol 2017;58:1198-1205.
doi: 10.1177/0284185117690421.
Schmitz AMT, Teixeira SC, Pengel KE, Loo CE, Vogel WV, Wesseling
J, et al. Monitoring tumor response to neoadjuvant chemotherapy
using MRI and 18F-FDG PET/CT in breast cancer subtypes. PLoS
One 2017;12:e0176782. doi: 10.1371/journal.pone.0176782.
Skarping I, Förnvik D, Zackrisson S, Borgquist S, Rydén L.
Predicting pathological axillary lymph node status with
ultrasound following neoadjuvant therapy for breast cancer.
Breast Cancer Res Treat 2021;189:131-44. doi: 10.1007/s10549-

7th AKU Annual Surgical Conference

19.

20.

21.

22.

021-06283-8.
Banys-Paluchowski M, Gruber IV, Hartkopf A, Paluchowski P,
Krawczyk N, Marx M, et al. Axillary ultrasound for prediction of
response to neoadjuvant therapy in the context of surgical
strategies to axillary dissection in primary breast cancer: a
systematic review of the current literature. Arch Gynecol Obstet
2020;301:341-53. doi: 10.1007/s00404-019-05428-x.
Fei J, Wang GQ, Meng YY, Zhong X, Ma JZ, Sun NN, et al. Breast
cancer subtypes affect the ultrasound performance for axillary
lymph node status evaluation after neoadjuvant chemotherapy: a
retrospective analysis. Jpn J Clin Oncol 2021;51:1509-14. doi:
10.1093/jjco/hyab117.
Di Micco R, Zuber V, Fiacco E, Carriero F, Gattuso MI, Nazzaro L, et
al. Sentinel node biopsy after primary systemic therapy in node
positive breast cancer patients: Time trend, imaging staging
power and nodal downstaging according to molecular subtype.
Eur J Surg Oncol 2019;45:969-75. doi: 10.1016/j.ejso.2019.01.219.
Ozmen T, Lazaro M, Vinyard A, Avisar E. Abstract P3-01-17:
Evaluation of "Systematic sonographic axillary staging" on
clinically node positive breast cancer patients becoming clinically
node negative after neoadjuvant chemotherapy. Cancer Res
2018;78(Suppl 4):P3-01-17. DOI: 10.1158/1538-7445.SABCS17-P301-17.

Vol. 72, No. 1 (Suppl. 1), January 2022

